Reviva Pharmaceuticals Holdings, Inc. S-8 Filing

FAQ

Key Financial Figures

• $0.0001 — f the Company's common stock, par value $0.0001 per share (the "Common Stock"), issuabl

Filing Documents

• rvph20260324_s8.htm (S-8) — 52KB
• ex_936632.htm (EX-5.1) — 7KB
• ex_936633.htm (EX-23.1) — 3KB
• ex_936634.htm (EX-FILING FEES) — 20KB
• lslogo.jpg (GRAPHIC) — 6KB
• 0001437749-26-010181.txt ( ) — 217KB
• ex_936634_htm.xml (XML) — 7KB

Incorporation of Documents by Reference

Item 3. Incorporation of Documents by Reference . The following documents filed by the Company with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are incorporated herein by reference: (a) The Company's latest annual report on Form 10-K filed pursuant to Section 13(a) or 15(d) of the Exchange Act for the fiscal year ended December 31, 2025, as filed with the Commission on March 30, 2026; (b) The Company's current reports on Form 8-K filed with the Commission on January 23, 2026 , March 5, 2026 and March 19, 2026 (other than any portions thereof deemed furnished and not filed); and (c) The description of Common Stock contained in the Company's Registration Statement on Form 8-A12B, as filed with the Commission on August 20, 2018 pursuant to Section 12(b) of the Exchange Act, as updated by the Description of Securities set forth on Exhibit 4.1 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the Commission on March 30, 2026, including any amendments or reports filed for the purpose of updating such description. All documents filed by the Company pursuant to Section 13(a), 13(c), 14, or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subs

Exhibits

Item 8. Exhibits . For a list of exhibits, see the Exhibit Index in this Registration Statement, which is incorporated into this Item by reference. EXHIBIT INDEX Exhibit No. Exhibit 4.1 Amended and Restated Certificate of Incorporation (filed as Exhibit 3.3 to the Company' s Current Report on Form 8-K (File No. 001-38634) as filed on December 18, 2020, and incorporated herein by reference) . 4.2 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Reviva Pharmaceuticals Holdings, Inc., dated December 10, 2024 (filed as Exhibit 3.1 to the Company' s Current Report on Form 8-K as filed on December 12, 2024, and incorporated herein by reference). 4.3 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Reviva Pharmaceuticals Holdings, Inc., dated December 18, 2025 (filed as Exhibit 3.1 to the Company' s Current Report on Form 8-K as filed on December 23, 2025 and incorporated herein by reference). 4.4 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Reviva Pharmaceuticals Holdings, Inc., dated March 4, 2026 (filed as Exhibit 3.1 to the Company ' s Current Report on Form 8-K as filed on March 5, 2026, and incorporated herein by reference). 4.5 Bylaws (filed as Exhibit 3.2 to the Company' s Current Report on Form 8-K (File No. 001-38634) as filed on December 14, 2020, and incorporated herein by reference). 4.6 Amendment No. 1, as adopted and approved by the Board of Directors on September 26, 2025, to the Bylaws of Reviva Pharmaceuticals Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company' s Current Report on Form 8-K filed with the SEC on September 26, 2025). 4.7 Specimen common stock certificate of the Company (filed as Exhibit 4.4 to the Company' s Form S-4 (File No. (333-245057) as filed on November 3, 2020, an incorporated herein by reference). 5.1* Legal Opinion of Lowenstein Sandler LLP. 23.1* Consent of Baker

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cupertino, State of California, on March 30, 2026. Reviva Pharmaceuticals Holdings, Inc. By: /s/ Laxminarayan Bhat Laxminarayan Bhat President and Chief Executive Officer KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned officers and directors of Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation, do hereby constitute and appoint each of Laxminarayan Bhat and Narayan Prabhu as his true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments to this Registration Statement on Form S-8), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated. Signature Title Date /s/ Laxminarayan Bhat President, Chief Executive Officer and Director March 30, 2026 Laxminarayan Bhat (Principal Executive Officer) /s/ Narayan Prabhu Chief Financial Offic

View Full Filing

View this S-8 filing on SEC EDGAR